Starting with a focus on cervical cancer, the Quad Countries—the U.S., Australia, India, and Japan—are launching a Cancer Moonshot initiative to strengthen the Indo-Pacific’s cancer care ecosystem. This initiative aims to expand research collaborations, build data systems, and provide greater support for cancer prevention, detection, treatment, and care.  This cervical…

A Phase II clinical study in women with advanced cervical cancer found that 22% of the patients treated with the bispecific antibody, bintrafusp alpha, experienced a tumor response, with 56% of these patients responding consistently for six months or more. The trial, published in JAMA Oncology, included 146 women in…

Researchers at Sweden’s Karolinska Institute and colleagues at the University of Innsbruck, Austria say they have a developed new screening method for cervical cancer that is both simpler and more effective than the current method used today. Their findings, published this week in Nature Medicine, show that that the new…

An international trial funded by Cancer Research UK and UCL Cancer Trials Centre has shown that adding a short course of chemotherapy prior to chemoradiation therapy (CRT) improves outcomes by substantially reducing the risk for relapse and death among patients with locally advanced cervical cancer. The induction chemotherapy (IC) regimen,…

New research points to lactate-producing intratumoral bacteria as a driving cause of radiation therapy resistance in cervical cancer. The study, published in Cancer Cell, found that Lactobacillus iners (L. iners), causes cervical cancer cells to respond to radiation by rewiring metabolic signaling pathways that ultimately lead to radiation resistance. The researchers also…

In a new study presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting, researchers have confirmed the effectiveness of two liquid biopsy tests in identifying patients at high risk of cervical cancer recurrence after completing chemoradiation. The tests, a digital polymerase chain reaction (dPCR) and a sequencing test…

Scientists at Montefiore Einstein Cancer Center (MECC) have developed a new test for detecting a type of cervical cancer that is often missed by traditional Pap tests. This breakthrough could have significant implications for cervical cancer screening. The findings of their research are published in the Journal of the National…

Research led by the Fourth Military Medical University in Xi’an, China, shows that the action of a specific micro (mi) RNA can suppress cervical cancer growth and that mimicking and boosting this action could be used as a therapeutic approach for these patients. The team found that higher levels of…

Sponsored content brought to you by. In February 2023, Seegene met with Dr. Marta del Pino at Eurogin, the leading international conference focused on human papilloma virus (HPV) and associated cancers, to discuss the value of HPV testing and genotyping in the new cervical cancer screening paradigm. Read on to…

A California study of women diagnosed with cervical cancer, finds that about 20% of new cases were in women 65 and older. The study, published in Cancer Epidemiology, Biomarkers & Prevention revealed that more older women were diagnosed with late-stage disease than younger women. Current guidelines from  the American Cancer…

The American Cancer Society (ACS) released today their annual report on cancer facts and trends, Cancer Statistics, 2023, showing overall cancer mortality has declined by 33% in the last 30 years, which translates to roughly 3.8 million deaths that were averted. The report also estimates that in the coming year,…

In the largest multiomics analysis of its kind, researchers have identified two distinct molecular subtypes of cervical cancer that have significantly different survival outcomes, potentially impacting future treatment decision-making. The past two decades have seen increasing use of molecular markers to subclassify cancers, which has brought increased understanding and, in…

Early stage cervical cancer rates fell by an annual 1.6%, but cases of advanced disease have increased by nearly 1.5% in the U.S. every year for the last couple of decades, a new study shows. The steepest rise in new cases of advanced womb (cervical) cancer in the U.S. is…

Sponsored content brought to you by Cervical cancer is caused almost exclusively by the human papilloma virus (HPV) and has a large mortality burden, especially in the developing world. HPV has a 7.9 kb genome and replicates in the nucleus as a circular, extrachromosomal element, termed an episome, by hijacking…

Cervical cancer is the most common gynecological cancer and is the fourth leading cause of cancer death among women worldwide. Despite advances in the understanding of the diseases and the development of new treatments, therapeutic approaches for women with recurrent or metastatic disease remain suboptimal. Yet results released in late…